Literature DB >> 27011908

Renal transplantation with expanded criteria donors: Which is the optimal immunosuppression?

Vassilis Filiopoulos1, John N Boletis1.   

Abstract

The growing gap between demand and supply for kidney transplants has led to renewed interest in the use of expanded criteria donor (ECD) kidneys in an effort to increase the donor pool. Although most studies of ECD kidney transplantation confirm lower allograft survival rates and, generally, worse outcomes than standard criteria donor kidneys, recipients of ECD kidneys generally have improved survival compared with wait-listed dialysis patients, thus encouraging the pursuit of this type of kidney transplantation. The relative benefits of transplantation using kidneys from ECDs are dependent on patient characteristics and the waiting time on dialysis. Because of the increased risk of poor graft function, calcineurin inhibitor (CNI)-induced nephrotoxicity, increased incidence of infections, cardiovascular risk, and malignancies, elderly recipients of an ECD kidney transplant are a special population that requires a tailored immunosuppressive regimen. Recipients of ECD kidneys often are excluded from transplant trials and, therefore, the optimal induction and maintenance immunosuppressive regimen for them is not known. Approaches are largely center specific and based upon expert opinion. Some data suggest that antithymocyte globulin might be the preferred induction agent for elderly recipients of ECD kidneys. Maintenance regimens that spare CNIs have been advocated, especially for older recipients of ECD kidneys. CNI-free regimens are not universally accepted due to occasionally high rejection rates. However, reduced CNI exposure and CNI-free regimens based on mammalian target of rapamycin inhibitors have shown acceptable outcomes in appropriately selected ECD transplant recipients.

Entities:  

Keywords:  Expanded-criteria donors; Immunosuppression; Kidney transplantation; Outcomes; Survival

Year:  2016        PMID: 27011908      PMCID: PMC4801786          DOI: 10.5500/wjt.v6.i1.103

Source DB:  PubMed          Journal:  World J Transplant        ISSN: 2220-3230


  70 in total

1.  Three-year outcomes from BENEFIT-EXT: a phase III study of belatacept versus cyclosporine in recipients of extended criteria donor kidneys.

Authors:  J O Medina Pestana; J M Grinyo; Y Vanrenterghem; T Becker; J M Campistol; S Florman; V D Garcia; N Kamar; P Lang; R C Manfro; P Massari; M D C Rial; M A Schnitzler; S Vitko; T Duan; A Block; M B Harler; A Durrbach
Journal:  Am J Transplant       Date:  2012-02-02       Impact factor: 8.086

2.  The risk of cancer in recipients of living-donor, standard and expanded criteria deceased donor kidney transplants: a registry analysis.

Authors:  Maggie K M Ma; Wai H Lim; Robin M Turner; Jeremy R Chapman; Jonathan C Craig; Germaine Wong
Journal:  Transplantation       Date:  2014-12-27       Impact factor: 4.939

3.  The combination of donor and recipient age is critical in determining host immunoresponsiveness and renal transplant outcome.

Authors:  Stefan G Tullius; Huong Tran; Indira Guleria; Sayeed K Malek; Nicholas L Tilney; Edgar Milford
Journal:  Ann Surg       Date:  2010-10       Impact factor: 12.969

4.  Increased immunogenicity and cause of graft loss of old donor kidneys.

Authors:  Johan W DE Fijter; Marko J K Mallat; Ilias I N Doxiadis; Jan Ringers; Frits R Rosendaal; Frans H J Claas; Leendert C Paul
Journal:  J Am Soc Nephrol       Date:  2001-07       Impact factor: 10.121

5.  Survival in recipients of marginal cadaveric donor kidneys compared with other recipients and wait-listed transplant candidates.

Authors:  Akinlolu O Ojo; Julie A Hanson; Herwig-Ulf Meier-Kriesche; Chike N Okechukwu; Robert A Wolfe; Alan B Leichtman; Lawrence Y Agodoa; Bruce Kaplan; Friedrich K Port
Journal:  J Am Soc Nephrol       Date:  2001-03       Impact factor: 10.121

6.  Donor characteristics associated with reduced graft survival: an approach to expanding the pool of kidney donors.

Authors:  Friedrich K Port; Jennifer L Bragg-Gresham; Robert A Metzger; Dawn M Dykstra; Brenda W Gillespie; Eric W Young; Francis L Delmonico; James J Wynn; Robert M Merion; Robert A Wolfe; Philip J Held
Journal:  Transplantation       Date:  2002-11-15       Impact factor: 4.939

7.  Differential outcomes of expanded-criteria donor renal allografts according to recipient age.

Authors:  Joshua D Mezrich; John D Pirsch; Luis A Fernandez; David P Foley; Janet M Bellingham; Jon S Odorico; Glen E Leverson; Alejandro Munoz-Del-Rio; Hans W Sollinger; Dixon B Kaufman; Anthony M D'Alessandro
Journal:  Clin J Am Soc Nephrol       Date:  2012-05-31       Impact factor: 8.237

8.  Aging augments IL-17 T-cell alloimmune responses.

Authors:  B M Tesar; W Du; A C Shirali; W E Walker; H Shen; D R Goldstein
Journal:  Am J Transplant       Date:  2008-10-31       Impact factor: 8.086

9.  Outcomes of kidney transplantation from older living donors to older recipients.

Authors:  Jagbir Gill; Suphamai Bunnapradist; Gabriel M Danovitch; David Gjertson; John S Gill; Michael Cecka
Journal:  Am J Kidney Dis       Date:  2008-07-24       Impact factor: 8.860

10.  Conversion to everolimus in kidney transplant recipients: to believe or not believe?

Authors:  P Cotovio; M Neves; L Santos; F Macário; R Alves; A Mota
Journal:  Transplant Proc       Date:  2012-12       Impact factor: 1.066

View more
  10 in total

1.  Recipient efficacy and safety of kidney transplantation from older living donor: consideration for using older kidney as a solution to the shortage of organs.

Authors:  Ji Yeon Song; Kyo Won Lee; Kyunga Kim; Kyeong Deok Kim; Jaehun Yang; Ji Eun Kwon; Okjoo Lee; Jae Berm Park
Journal:  Korean J Transplant       Date:  2021-12-31

2.  Doxycycline Alters the Porcine Renal Proteome and Degradome during Hypothermic Machine Perfusion.

Authors:  Leonie van Leeuwen; Leonie H Venema; Raphael Heilig; Henri G D Leuvenink; Benedikt M Kessler
Journal:  Curr Issues Mol Biol       Date:  2022-01-23       Impact factor: 2.976

3.  Evolving Trends in Racial Disparities for Peri-Operative Outcomes with the New Kidney Allocation System (KAS) Implementation.

Authors:  Daisy Sanchez; Derek Dubay; Baliga Prabhakar; David J Taber
Journal:  J Racial Ethn Health Disparities       Date:  2018-03-19

4.  Association of Clinical Events With Everolimus Exposure in Kidney Transplant Patients Receiving Low Doses of Tacrolimus.

Authors:  F Shihab; Y Qazi; S Mulgaonkar; K McCague; D Patel; V R Peddi; D Shaffer
Journal:  Am J Transplant       Date:  2017-03-04       Impact factor: 8.086

5.  Results of Kidney Transplantation from Expanded Criteria Donors: A Single-Center Experience.

Authors:  B Palkoci; M Vojtko; J Fialová; D Osinová; M Lajčiaková
Journal:  Int J Organ Transplant Med       Date:  2018-02-01

6.  Implementing of Active Brain-Dead Donor Identification Strategy in a Single Donor Center: One Year Experience.

Authors:  Akvilina Trilikauskienė; Irena Maraulaitė; Diana Damanskytė; Dovilė Lukminaitė; Neringa Balčiūnienė; Tomas Tamošuitis
Journal:  Medicina (Kaunas)       Date:  2020-07-22       Impact factor: 2.430

7.  Assessing the Outcome of Adult Kidney Transplantation from a Deceased Expanded Criteria Donor: A Descriptive Study.

Authors:  Mona Alshahrani; Mutlaq Alotaibi; Burhan Bhutto
Journal:  Cureus       Date:  2020-10-27

Review 8.  Shifting Paradigms for Suppressing Fibrosis in Kidney Transplants: Supplementing Perfusion Solutions With Anti-fibrotic Drugs.

Authors:  L Leonie van Leeuwen; Henri G D Leuvenink; Peter Olinga; Mitchel J R Ruigrok
Journal:  Front Med (Lausanne)       Date:  2022-01-10

Review 9.  Machine Perfusion of Extended Criteria Donor Organs: Immunological Aspects.

Authors:  Mindaugas Kvietkauskas; Bettina Leber; Kestutis Strupas; Philipp Stiegler; Peter Schemmer
Journal:  Front Immunol       Date:  2020-02-27       Impact factor: 7.561

Review 10.  Transplantation of Marginal Organs: Immunological Aspects and Therapeutic Perspectives in Kidney Transplantation.

Authors:  Johan Noble; Thomas Jouve; Paolo Malvezzi; Caner Süsal; Lionel Rostaing
Journal:  Front Immunol       Date:  2020-01-31       Impact factor: 7.561

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.